A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder
Completed · Phase 1 · Has a placebo group
Conditions studied: Depressive Disorder, Major
In brief
The purpose of this study is to explore if the magnitude of treatment effect (JNJ-42847922; placebo) on symptoms of depression (as measured by Hamilton rating scale for depression-17 \[HDRS17\], Sleep item-adjusted HDRS17, Anxiety/somatization factor score and the 6-item subscale from HDRS17 \[HAM-D6\]) differs across different levels of hyper-arousal status (characterized by Sleep parameters, ruminative response scale \[RRS\], Sleep and Worry visual analogue scale \[VAS\], quantitative electro-encephalography \[qEEG\], heart rate variability \[HRV\] and others).
Key facts
- Study ID
- NCT03374475
- Run by
- Janssen Research & Development, LLC
- People needed
- 140
- Starts
- 2018-01-05
- Expected to finish
- 2019-04-29
- Last updated by the study team
- 2025-04-27
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have a body mass index (BMI) between 18 and 35 kilogram per meter square (kg/m\^2) inclusive (BMI = weight/height\^2)
- Participants must be medically stable based on clinical laboratory tests, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and baseline
- Population specific: Participant must meet Diagnostic and Statistical Manual of Mental Disorders - fifth edition (DSM-5) diagnostic criteria for MDD (international classification of diseases [ICD]-code F32.x and F33.x), without psychotic features, and confirmed by the Mini International Neuropsychiatric Interview (MINI) 7.0; have a Montgomery Asberg Depression Rating Scale (MADRS) total score greater than or equal to (>=) 25 at screening and must not demonstrate a clinically significant change (that is, an improvement of greater than (>) 20 percent (%) on their MADRS total score) from the screening to the second completion of MADRS by telephone at most 4 days before the baseline visit; Not currently receiving antidepressant drug therapy for >= 2 weeks before screening
- Men who are sexually active with a women of childbearing potential (WOCBP) and have not had a vasectomy must agree to use a barrier method of birth control
- A woman of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test before the first dose
- A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for at least 3 months after receiving the last dose of study drug
You may not qualify if…
- Has failed more than 2 treatments (no more than 20 percent (%) response) with a differing pharmacological mode of action despite an adequate dose and duration during a previous, or the current depressive episode
- Has a diagnosis of Cushing's Disease, Addison's Disease, primary amenorrhea, or other evidence of significant medical disorders of the Hypothalamus pituitary adrenal (HPA) axis
- Is pregnant or breast feeding
- Participant has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 60 days before the planned first dose of study drug, or has participated in 2 or more interventional clinical studies in the previous 1 year, or is currently enrolled in an interventional study
- Participant is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug
- Participant has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at screening
Where it is running
- Artemis Institute for Clinical Research — San Diego, California, United States
- Artemis Institute for Clinical Research — San Marcos, California, United States
- Qps-Mra, Llc — Miami, Florida, United States
- SGS Phase 1 Unit AZ St-Maarten — Mechelen, Belgium
- Clinical Pharmacology Unit — Merksem, Belgium
- Charite Research Organisation GmbH — Berlin, Germany
- Emovis GmbH — Berlin, Germany
- Fraunhofer-Institut für Toxikologie und Experimentelle Medizin — Hanover, Germany
- Somni Bene GmbH — Schwerin, Germany
- Centre for Human Drug Research — Leiden, Netherlands
- MAC Clinical Research — Blackpool, United Kingdom
- MAC Clinical Research — Liverpool, United Kingdom
- Hammersmith Medicines Research — London, United Kingdom
- MAC Clinical Research — Manchester, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.